Literature DB >> 16087201

Pro-VGF-derived peptides induce penile erection in male rats: Involvement of paraventricular nitric oxide.

Salvatora Succu1, Maria Stefania Mascia, Tiziana Melis, Fabrizio Sanna, Maria Rosaria Melis, Roberta Possenti, Antonio Argiolas.   

Abstract

The effect of four peptides derived from the C-terminal portion of rat pro-VGF(556-617) (VGF(556-576), VGF(588-617), VGF(599-617), and VGF(588-597)), on penile erection and nitric oxide production in the paraventricular nucleus of the hypothalamus was studied in male rats after injecting into this hypothalamic nucleus. VGF(588-617) (0.5, 1 and 2 microg), VGF(599-617) (0.5, 2 and 5 microg) and, to a lower extent, VGF(588-597) (2 and 5 microg) induced penile erection episodes when injected into the paraventricular nucleus and concomitantly increased paraventricular nitric oxide production, while VGF(556-576) (5 microg) was ineffective. VGF(588-617)-induced nitric oxide production was reduced by N(G)-nitro-l-arginine methylester (l-NAME) (20 microg), a nitric oxide synthase inhibitor, which also reduced penile erection when injected in the paraventricular nucleus 15 min before the VGF peptide. The oxytocin receptor antagonist d(CH(2))(5)Tyr(Me)-Orn(8)-vasotocin (1 microg) also effectively reduced VGF(588-617)-induced penile erection when given into the lateral ventricles, but not when injected into the paraventricular nucleus. In both experimental conditions, d(CH(2))(5)Tyr(Me)-Orn(8)-vasotocin was unable to influence nitric oxide production in the paraventricular nucleus. The present results confirm that C-terminal pro-VGF-derived peptides induce penile erection when injected into the paraventricular nucleus and show that this effect is mediated by an increased nitric oxide production in this hypothalamic nucleus. Apparently, this causes the activation of paraventricular oxytocinergic neurons projecting to extra-hypothalamic brain areas and mediating penile erection, as found with dopamine agonists, oxytocin, excitatory amino acids and hexarelin analogue peptides.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16087201     DOI: 10.1016/j.neuropharm.2005.05.015

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  13 in total

1.  Proteomic analysis uncovers novel actions of the neurosecretory protein VGF in nociceptive processing.

Authors:  Maureen S Riedl; Patrick D Braun; Kelley F Kitto; Samuel A Roiko; Lorraine B Anderson; Christopher N Honda; Carolyn A Fairbanks; Lucy Vulchanova
Journal:  J Neurosci       Date:  2009-10-21       Impact factor: 6.167

Review 2.  The extended granin family: structure, function, and biomedical implications.

Authors:  Alessandro Bartolomucci; Roberta Possenti; Sushil K Mahata; Reiner Fischer-Colbrie; Y Peng Loh; Stephen R J Salton
Journal:  Endocr Rev       Date:  2011-08-23       Impact factor: 19.871

3.  Role of VGF-derived carboxy-terminal peptides in energy balance and reproduction: analysis of "humanized" knockin mice expressing full-length or truncated VGF.

Authors:  Masato Sadahiro; Connor Erickson; Wei-Jye Lin; Andrew C Shin; Maria Razzoli; Cheng Jiang; Samira Fargali; Allison Gurney; Kevin A Kelley; Christoph Buettner; Alessandro Bartolomucci; Stephen R Salton
Journal:  Endocrinology       Date:  2015-02-12       Impact factor: 4.736

Review 4.  Neuropeptides in depression: role of VGF.

Authors:  Smita Thakker-Varia; Janet Alder
Journal:  Behav Brain Res       Date:  2008-10-15       Impact factor: 3.332

Review 5.  Secretogranin III: a diabetic retinopathy-selective angiogenic factor.

Authors:  Wei Li; Keith A Webster; Michelle E LeBlanc; Hong Tian
Journal:  Cell Mol Life Sci       Date:  2017-08-30       Impact factor: 9.261

Review 6.  Looking to the future for erectile dysfunction therapies.

Authors:  Konstantinos Hatzimouratidis; Dimitrios G Hatzichristou
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  In vitro and in vivo pharmacological role of TLQP-21, a VGF-derived peptide, in the regulation of rat gastric motor functions.

Authors:  C Severini; G La Corte; G Improta; M Broccardo; S Agostini; C Petrella; V Sibilia; F Pagani; F Guidobono; I Bulgarelli; G L Ferri; C Brancia; A M Rinaldi; A Levi; R Possenti
Journal:  Br J Pharmacol       Date:  2009-05-19       Impact factor: 8.739

8.  An inducer of VGF protects cells against ER stress-induced cell death and prolongs survival in the mutant SOD1 animal models of familial ALS.

Authors:  Masamitsu Shimazawa; Hirotaka Tanaka; Yasushi Ito; Nobutaka Morimoto; Kazuhiro Tsuruma; Michinori Kadokura; Shigeki Tamura; Teruyoshi Inoue; Mitsunori Yamada; Hitoshi Takahashi; Hitoshi Warita; Masashi Aoki; Hideaki Hara
Journal:  PLoS One       Date:  2010-12-09       Impact factor: 3.240

Review 9.  Future prospects in the treatment of erectile dysfunction: focus on avanafil.

Authors:  Amjad Alwaal; Raed Al-Mannie; Serge Carrier
Journal:  Drug Des Devel Ther       Date:  2011-10-18       Impact factor: 4.162

10.  The role of the vgf gene and VGF-derived peptides in nutrition and metabolism.

Authors:  Alessandro Bartolomucci; Roberta Possenti; Andrea Levi; Flaminia Pavone; Anna Moles
Journal:  Genes Nutr       Date:  2007-10-18       Impact factor: 5.523

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.